Seroprevalence and Genetic Characterization of Toxoplasma gondii among Children with Neurodevelopmental Disorders in Egypt

Table 1

Toxoplasmosis seroprevalence and molecular positivity rates among the patient group (children with neurodevelopmental disorders) and control group.

Parameter	Study participants		value
	Patient group (n = 180)	Control group (n = 180)
Overall anti-Toxoplasma antibodies seroprevalence n (%)	64 (35.6)	21 (11.7)	<0.001
Anti-toxoplasma IgM seropositivity n (%)	18 (10)	2 (1.1)	0.04
Anti-toxoplasma IgG seropositivity n (%)	42 (23.3)	18 (10)	<0.001
Anti-toxoplasma IgM and IgG seropositivity n (%)	4 (2.2)	1 (0.5)	0.78
Anti-toxoplasma IgG concentration (IU/ml)∗	309.83 (33.9–409.65)	61.13 (35.76–97.8)	<0.001
Positive PCR for Toxoplasma DNA n (%)	20 (11.1)	1 (0.5)	0.03

n: number of participants. Data was represented as medium and range (Min–Max).